Navigation Links
Growth Hormone Won't Fight ALS
Date:11/24/2008

Study shows 'disappointing' results against Lou Gehrig's disease

MONDAY, Nov. 24 (HealthDay News) -- The growth hormone known as insulin-like growth factor-1 (IGF-1) showed no benefit for people with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

The two-year U.S. study included 330 patients from 20 medical centers.

Two previous, shorter studies had produced conflicting results. One North American study found that IGF-1 was beneficial, while a European study found no benefit for people with ALS, a progressive, fatal neurodegenerative disease that causes muscles to weaken and deteriorate.

This new study concluded that IGF-1 does not slow progression of muscle weakness.

"It's disappointing that we were not able to confirm the benefit that was found in the North American study. The current treatment options for ALS are inadequate, and more effective treatments are vitally needed," study author Dr. Eric J. Sorenson, of the Mayo Clinic in Rochester, Minn., said in an American Academy of Neurology news release.

Half the patients in the new study were given injections of IGF-1 while the other half received a placebo. The patients' muscle strength was tested at the start of the study and again five times during the two-year study period. Sorenson and his colleagues also tracked how long patients went without needing a tracheostomy (a tube inserted in the neck to assist breathing) and their scores on ongoing tests of their ability to perform daily activities.

The study found no differences between the two groups in muscle strength, how long they went without needing a tracheostomy, or in their ability to perform daily activities.

The findings were published in the Nov. 25 issue of the journal Neurology.

More information

The Muscular Dystrophy Association has more about ALS.



-- Robert Preidt



SOURCE: American Academy of Neurology, news release, Nov. 24, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sermes CRO Deploys Oracle(R) Clinical Applications to Support Growth
2. Frutarom Continues to Implement its Rapid Growth Strategy
3. Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
4. Growth Hormone Boost May Not Slow Alzheimers
5. In a Down Economy, Womens Health Company Announces Growth
6. PaperThin Experiences Record Growth : Grows Revenues, Expands Channel, and Maintains 95%+ Subscription Renewal Rate
7. Lees Pharmaceutical Kept Up the Rapid Pace of Growth; Profit Attributable to Shareholders Surged 176% in the Nine Months of 2008
8. The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance
9. Researchers find stem cells from monkey teeth can stimulate growth and generation of brain cells
10. Signaling between protein, growth factor is critical for coordinated cell migration
11. NHPCO Reports Growth in Number of Hospice Patients Served, 1.4 Million, With a Wider Range of Illnesses Seen by Providers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Growth Hormone Won't Fight ALS
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known for ... people know that popular cosmetic fillers can enhance earlobes and rejuvenate ... director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. ...
(Date:1/18/2017)... ... 2017 , ... Delaware farmer Rick Dickerson attended the 2017 Soybean Leadership ... farms about a thousand acres of soybeans, corn and wheat, and raises peas, sweet ... other vegetables for the fresh market. He also operates a roadside stand and raises ...
(Date:1/18/2017)... ... January 18, 2017 , ... Visually ... number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating and hyperhidrosis are ... Dri created this infographic to explain the seven types of hyperhidrosis. This visual ...
(Date:1/18/2017)... ANN ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, ... ... (PRWEB) January 18, 2017 -- Global public ... pitcher to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: ... Standard for drinking water treatment units. This certification verifies that ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced today ... compete in the Boston Marathon on April 17. From first-time participants to accomplished ... to join Team V and support the Foundation’s mission to declare victory over cancer. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
(Date:1/19/2017)... FRANCISCO , January 19, 2017 The global  pacemaker ... new report by Grand View Research, Inc. The heightening prevalence of cardiac conditions ... the growth of Pacemaker globally. In addition, technological enhancements in these devices are ... ... Grand View Research Logo ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
Breaking Medicine Technology: